ArticleYonsei medical journal2025
Clinical Outcomes of Photodynamic Therapy for Choroidal Nevus with Subfoveal Fluid.
Article in Yonsei medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeTo evaluate the outcomes of photodynamic therapy (PDT) for choroidal nevus associated with subfoveal fluid. MATERIALS AND
methodsElectronic medical records were reviewed for patients diagnosed with choroidal nevus and treated with PDT at a single center in Seoul, South Korea, from January 2019 to December 2023. Patient demographics, tumor characteristics, and clinical progress following PDT, including changes in foveal subretinal fluid (SRF) height, central subfield thickness (CST), corrected distant visual acuity (CDVA), tumor size, and fluid recurrence, were analyzed.
resultsSeven eyes of seven patients were included; all had SRF involving the foveal center and associated visual symptoms. The median diameter and thickness of tumors were 4.10 mm (range 3.2-5.5 mm) and 0.80 mm (range 0.6-1.4 mm), respectively. All patients received a single PDT session, with a mean follow-up of 20.6 months. Subfoveal fluid decreased in 6 patients (85.7%), with complete resolution in 4 eyes (57.1%); 1 patient showed no significant change after PDT. Consequently, the mean foveal SRF height decreased from 135.9±83.0 µm to 20.3±31.9 µm, and CST from 365.7±82.5 µm to 258.1±52.7 µm. CDVA improved in 1 patient (14.3%), remained stable in 3 (42.9%), and decreased in 2 (28.6%). Three of six patients with reduced subfoveal fluid experienced recurrence at 3 months, 3 months, and 21 months after PDT.
conclusionPDT demonstrated noticeable efficacy in reducing subfoveal fluid associated with choroidal nevus within 1 month of treatment. However, in some cases, the effect may be limited in long-term maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.